



# Market Announcement

29 June 2020

---

## Amplia Therapeutics Limited (ASX: ATX) – Trading Halt

### Description

The securities of Amplia Therapeutics Limited ('ATX') will be placed in trading halt at the request of ATX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 1 July 2020 or when the announcement is released to the market.

### Issued by

**Corey Lian**

Adviser, Listings Compliance (Sydney)

Mr. Corey Lian  
Adviser, Listings Compliance (Sydney)  
Australian Securities Exchange

29 June 2020

[corey.lian@asx.com.au](mailto:corey.lian@asx.com.au)

&

[tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

### **REQUEST FOR TRADING HALT**

Amplia Therapeutics Limited (ASX Code: ATX) requests an immediate Trading Halt in the securities of the Company.

For the purposes of Listing Rule 17.1 , ATX provides the following information:

- a) The Trading Halt is to allow the Company to verify preliminary final results from preclinical toxicology studies and finalise an appropriate market announcement.
- b) The Company requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to preclinical toxicology studies and the commencement of trading on Wednesday, 1 July 2020.
- c) The event which the Company expects will end the trading halt will be the lodgement of an announcement regarding preclinical toxicology studies.
- d) The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely,



**Andrew J Cooke**  
Company Secretary

#### **About Amplia Therapeutics Limited**

Amplia Therapeutics is a biopharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) small molecule inhibitors to address serious unmet medical needs in cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a development focus in pancreatic and ovarian cancer. FAK may also play a significant biological role in the progression of chronic fibrotic diseases, such as hepatic fibrosis and idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics is listed on the Australian Securities Exchange (ASX.ATX). For information about Amplia Therapeutics and its pipeline, please visit our website at [www.ampliatx.com](http://www.ampliatx.com)